Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

The One Nasdaq approach continued to accelerate cross-selling opportunities, with the company on track to surpass $100 million in run-rate revenue from cross-sells by the end of 2027. Cross-sells now ...

IFSCA releases 2025 Master Circular for IFSC investment bankers, introduces SWITS for streamlined registration and compliance ...

Quarterly Fee-Related Earnings Up 16% Year-Over-Year and 18% Over the Last Twelve Months $22B of Capital Raised in the Quarter and $97B Raised Over the Last Twelve Months NEW YORK, Aug. 06, 2025 ...